May 15, 2013
  • New Study Raises Questions About FDA Warning
    on Citalopram

    While the FDA has warned against use of the antidepressant citalopram at greater than 40 mg because of the risk for abnormal heart rhythms, a new study was unable to identify increased incidences of adverse cardiac events when the drug was administered at higher doses. Find out the study results and why the authors contend the FDA warning may be doing more harm than good.

  • Recommendations Spell Out Acne Treatment for Children, Infants

    Acne occurs in children as young as newborns, but many of the treatment protocols have focused on adolescents. Now, new recommendations endorsed by the American Academy of Pediatrics give specific guidance on how to treat acne vulgaris in infants and younger children prepuberty. Here are the specifics.

  • FDA: Valproate Sodium, Related Products Not for Use by Pregnant Women

    In light of a recent FDA advisory and label change, pharmacists should advise pregnant women taking valproate products to contact their prescribers immediately. The antiseizure medications are now contraindicated in pregnant women for migraine and should only be used in epilepsy or bipolar disorders as a last resort. Here are the details.

  • Testosterone Therapy Increases Insulin Sensitivity in Males With Type 2 Diabetes

    Studies are finding that the benefits of testosterone therapy could be far beyond just the improvement of sexual performance in men. The latest, from a presentation at a recent endocrinology conference, suggests that testosterone therapy can significantly increase insulin sensitivity in men with both type 2 diabetes and hypogonadism.

U.S. Pharmacist Social Connect